GPCR Therapeutics Expands US Facilities with Relocation to Redwood City

Redwood City, California, September 7, 2022 – GPCR Therapeutics, Inc., a venture-backed clinical stage international biopharmaceutical company with an innovative approach to drug discovery based on targeting G Protein Coupled Receptors (GPCR) pairs, today announced that to accommodate the expansion of its US subsidiary, it has relocated from incubator space in San Carlos. GPCR’s US operations will be based in new office and laboratory space at 400 Seaport Court, Redwood City, a premier location for biotech research in the San Francisco Bay Area.

Read full release